

Indoco's Revenues grows by 11.8% Y-o-Y

May 28, 2013

May 28, 2013, Mumbai: Indoco Remedies Limited, a pharmaceutical Company with global presence, recorded revenues at Rs. 1604.8 million during the fourth quarter of FY 2012-13 as compared to Rs. 1476.6 million over the same quarter last year. The un-audited results for the fourth quarter of the financial year 2012-13 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on May 28, 2013.

Commenting on the performance, Mr. Suresh G. Kare, Executive Chairman said, "I am glad that the domestic formulation sales in the fourth quarter surpassed the industry average growth rate. The much awaited Drug Pricing Policy has now been announced and the impact on the Company is marginal. The business from USA is expected to ramp up with a few ANDAs slated for approval thereby giving boost to the International Business revenues. Going forward, the Company will accelerate sales growth with improved margins."

HIGHLIGHTS:

Fourth Quarter ended March 2013 of FY 2012-13

Net Revenues at Rs. 1604.8 million

EBIDTA at Rs. 282.2 million

Profit After Tax at Rs. 128.5 million

EPS at Rs. 1.39

(Face value of Rs. 2/- per share after split & bonus)

Year ended March 2013 of FY 2012-13

Net Revenues at Rs. 6264.3 million

EBIDTA at Rs. 1059.8 million

Profit After Tax at Rs. 426.6 million

EPS at Rs. 4.63

(Face value of Rs. 2/- per share after split & bonus)

The consolidated EBIDTA for the year stood at Rs. 1061.6 million, operating profit at Rs. 605.6 million and Profit After Tax (PAT) at Rs. 427.2 million.